Cusi K, et al. - In this double-blind, parallel-group, placebo-controlled, 24-week trial, researchers assessed the effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on intrahepatic triglyceride (IHTG) accumulation and its relationship to changes in body weight and glucose metabolism. For this investigation, patients with insufficiently controlled type 2 diabetes mellitus ((T2DM) from two centres were randomly assigned (1:1) to canagliflozin 300 mg or placebo. There were 56 patients enrolled between September 8, 2014, and June 13, 2016. Investigators found that body weight and HbA1c were lowered by canagliflozin. In patients with T2DM, canagliflozin improves hepatic insulin sensitivity and insulin secretion and clearance. With canagliflozin, the sensitivity of beta-cell glucose, insulin clearance and disposition index improved further. Findings revealed that IHTG decreases in proportion to the magnitude of body weight loss tending to be higher and occurring more frequently with canagliflozin.